New treatment for advanced endometrial cancer after prior therapy
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have advanced or recurrent endometrial cancer that has spread or come back.
- You have tried and failed 2 or fewer prior cancer treatments (hormone therapy does not count).
- Your previous immunotherapy (PD-1 or PD-L1 blocker) worked for at least 6 months before it stopped working.
- You have not had a type of immunotherapy called PD-1/CTLA-4 dual-target therapy before.
- You do not have active autoimmune disease or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of drugs for advanced solid tumors. It may help if your cancer has not responded to other treatments, and the goal is to see how safe and effective this new approach is.
This trial tests a new medicine called QL1706 (a type of immunotherapy that helps your immune system fight cancer) combined with chemotherapy for women with advanced or recurrent endometrial cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests a new combination of an immunotherapy drug (QL1706) and two chemotherapy medicines (AG) as the first treatment for advanced pancreatic cancer. The goal is to see if the combination can shrink tumors and help patients live longer.
This trial tests a new immunotherapy drug (QL1706) for cervical cancer that has stopped responding to earlier PD-1 therapies. The goal is to see if this drug can help shrink tumors or slow down the cancer.
This trial tests a new drug (QL1706) combined with bevacizumab, with or without chemotherapy, for people with advanced non-squamous non-small cell lung cancer that has grown after prior immunotherapy. It aims to see if this combination can help control the cancer.
Hear when a new Endometrial Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.